The Effect of genetic polymorphism of CYP2B6 and UGT1A9 on the Pharamcokinetics and Pharmacodynamics of Propofol

The Effect of genetic polymorphism of CYP2B6 and UGT1A9 on the Pharamcokinetics and Pharmacodynamics of Propofol - The genetic polymorphism is related to pharmacodynamics of propofol

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000002009

Enrollment

100

Registered

2009-05-26

Start date

2009-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The patients are surgical operation with propofol in the St. Marianna University Hospital

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients using propofol as an anesthetics

Exclusion criteria

Exclusion criteria: The patients did not informed consent. The propofol administration dosage is varied. The patients are transfusion during surgical operation. The patients have infection. The patients is under the confusion, ileus, agnosis, resection of stomach, disorder of liver function, disorder of kidney function, suppress of breathing, chronic obstructive pulmonary disease, asthma, heart failure with chronic pulmonary disease, and/or seizure. The medical doctor is estimate that the patients cannot entry of study

Design outcomes

Primary

Measure	Time frame
The recovery of consciousness time, polymorphism of CYP2B6 and UGT1A9	—

Secondary

Measure	Time frame
Pharmacokinetics parameter of propofol	—

Countries

Japan

Contacts

Public ContactToshio Kumai

St. Marianna University School of Medicine Department of Pharmacogenomics

kumai@marianna-u.ac.jp044-977-8111

Outcome results